LYMPHOMA

Feature

Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma

A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.

Latest News

Dose-Adjusted Immunochemotherapy May Yield Durable Remission in Aggressive Diffuse Large B-Cell Lymphoma

By

Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.

Improved Outcomes for Vitreoretinal Lymphoma With Combined Treatment

By

Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.

CAR T Cell Therapy May Yield Durable Response in Relapsed/Refractory Diffuse Large B Cell Lymphoma

By

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.

First Rituximab Biosimilar Truxima Gets FDA Approval

By Da Hee Han, PharmD

The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.

Prevention of Hepatitis B Virus Reactivation in Patients With B-Cell Lymphoma

By

Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.

Adcetris Plus Chemotherapy Approved for Peripheral T-Cell Lymphoma

By Diana Ernst, RPh

The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.

Long-Term Survival in Patients With Advanced Stage Hodgkin Lymphoma

By

Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.

5-Azacitidine May Lead to Sustained Response in Peripheral T-Cell Lymphoma

By

Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.

Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas

By Zahra Masoud

Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.

New Assay May Aid Identification of Primary Mediastinal B-Cell Lymphoma

By

The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.

Symptomatic Osteonecrosis as a Treatment Complication in Hodgkin Lymphoma

By

Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

By Christina Bennett, MS

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

By Christina Bennett, MS

The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

By Randi Hernandez

Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

By James Nam, PharmD

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

By James Nam, PharmD

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

By James Nam, PharmD

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

By James Nam, PharmD

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

By James Nam, PharmD

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

By James Nam, PharmD

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

SIGN UP FOR FREE E-NEWSLETTERS